Loading...
Does rasagiline, a monoamine oxide type B inhibitor, retard the progression of Parkinson disease (PD)? The challenge in this situation is to demonstrate a disease-modifying effect distinct from the drug's clear beneficial effect on motor symptoms. In this study, researchers used a novel delayed-start design in which patients were randomized to receive either rasagiline (1 mg or 2 mg) or placebo for the first 36 weeks, followed by rasagiline for all participants for another 36 weeks. Three endpoints had to be met: slower progression with early rasagiline between 12 and 36 weeks, comparable progression between weeks 48 and 72 (i.e., no “catching up” in the delayed-start group), and a significant between-group difference in motor disability at…